Business Context and Reporting Period
This Form 8-K is a current report filed by Angion Biomedica Corp. (not Elicio Therapeutics, Inc.) on March 2, 2022. The filing discloses compensation matters approved by the Compensation Committee and Board of Directors regarding executive base salaries and equity awards effective for the 2022 fiscal year.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- 2022 Base Salaries:
- Jay Venkatesan (CEO): $608,000
- John Neylan (EVP, CMO): $485,100
- Jennifer J. Rhodes (EVP, CBO): $440,840
- 2021 Cash Bonuses: No discretionary cash bonuses were awarded to executives for 2021.
- Stock Option Grants (Annual Awards):
- CEO: 600,000 shares (Exercise Price: $1.94)
- CMO: 175,000 shares (Exercise Price: $1.99)
- CBO: 175,000 shares (Exercise Price: $1.99)
- CFO: 100,000 shares (Exercise Price: $1.99)
- Stock Option Grants (Enhanced Awards):
- CEO: 160,000 shares (Exercise Price: $1.94)
- CMO: 100,000 shares (Exercise Price: $1.99)
- CBO: 100,000 shares (Exercise Price: $1.99)
Material Changes
The filing details the establishment of 2022 annual base salaries effective January 1, 2022. It explicitly notes that executives did not receive a 2021 discretionary cash bonus. The filing also introduces "enhanced incentive" stock options intended to drive stockholder value in 2022, which vest on specific dates in July and December 2022, differing from the standard four-year monthly vesting schedule of the annual awards.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to the rationale for the enhanced equity awards, which are designed to incentivize executives to drive stockholder value in 2022.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2021 Incentive Award Plan to ensure sufficient capacity for these grants.
- Confirm the dilution impact of the 1,310,000 total option shares granted to the named executives.
- Review the vesting schedules to understand the timing of potential share issuance (monthly over 4 years vs. lump sums in 2022).
- Check the company's cash position to ensure it can sustain the increased annual salary obligations.